OwlTail

Cover image of Gail J. Roboz

Gail J. Roboz

13 Podcast Episodes

Latest 28 Aug 2021 | Updated Daily

Weekly hand curated podcast episodes for learning

Episode artwork

Gail J. Roboz, MD - Clinical Consults on Modern AML Therapy: Where Precision Care Meets Potent Therapeutics

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Go online to PeerView.com/GXY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this Clinical Consults webcast, a panel of experts looks at modern AML therapeutics that have transformed practice in high-risk, good-prognosis, mutation-defined, and post-remission settings (such as TP53-mutant AML, IDH and FLT3 mutation-positive disease, among others). Our experts offer guidance on how disease biology drives treatment decisions and on the use of newer cytotoxic strategies, targeted agents, epigenetic modifiers, and antibody-based treatment. Upon completion of this accredited CE activity, participants should be better able to: Describe factors for prognostic assessment and selection of treatment for patients with AML, including a diagnosis of CBF-AML; secondary AML; or AML with intermediate cytogenetics or TP53, FLT3, and/or IDH mutations, Summarize updated clinical evidence surrounding the use of novel cytotoxic, antibody, epigenetic, or targeted strategies, including novel combination strategies, for a range of AML patient populations and treatment settings, including upfront and post-remission therapy or in the management of relapsed/refractory AML, Design a personalized treatment plan for patients with newly diagnosed or relapsed/refractory AML who present with favorable, intermediate, or poor prognostic factors, Develop management protocols for unique adverse events associated with the use of novel therapeutics for AML.

1hr 31mins

20 Jul 2021

Episode artwork

Gail J. Roboz, MD - Clinical Consults on Modern AML Therapy: Where Precision Care Meets Potent Therapeutics

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/GXY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this Clinical Consults webcast, a panel of experts looks at modern AML therapeutics that have transformed practice in high-risk, good-prognosis, mutation-defined, and post-remission settings (such as TP53-mutant AML, IDH and FLT3 mutation-positive disease, among others). Our experts offer guidance on how disease biology drives treatment decisions and on the use of newer cytotoxic strategies, targeted agents, epigenetic modifiers, and antibody-based treatment. Upon completion of this accredited CE activity, participants should be better able to: Describe factors for prognostic assessment and selection of treatment for patients with AML, including a diagnosis of CBF-AML; secondary AML; or AML with intermediate cytogenetics or TP53, FLT3, and/or IDH mutations, Summarize updated clinical evidence surrounding the use of novel cytotoxic, antibody, epigenetic, or targeted strategies, including novel combination strategies, for a range of AML patient populations and treatment settings, including upfront and post-remission therapy or in the management of relapsed/refractory AML, Design a personalized treatment plan for patients with newly diagnosed or relapsed/refractory AML who present with favorable, intermediate, or poor prognostic factors, Develop management protocols for unique adverse events associated with the use of novel therapeutics for AML.

1hr 31mins

20 Jul 2021

Similar People

Episode artwork

Gail J. Roboz, MD - Clinical Consults on Modern AML Therapy: Where Precision Care Meets Potent Therapeutics

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/GXY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this Clinical Consults webcast, a panel of experts looks at modern AML therapeutics that have transformed practice in high-risk, good-prognosis, mutation-defined, and post-remission settings (such as TP53-mutant AML, IDH and FLT3 mutation-positive disease, among others). Our experts offer guidance on how disease biology drives treatment decisions and on the use of newer cytotoxic strategies, targeted agents, epigenetic modifiers, and antibody-based treatment. Upon completion of this accredited CE activity, participants should be better able to: Describe factors for prognostic assessment and selection of treatment for patients with AML, including a diagnosis of CBF-AML; secondary AML; or AML with intermediate cytogenetics or TP53, FLT3, and/or IDH mutations, Summarize updated clinical evidence surrounding the use of novel cytotoxic, antibody, epigenetic, or targeted strategies, including novel combination strategies, for a range of AML patient populations and treatment settings, including upfront and post-remission therapy or in the management of relapsed/refractory AML, Design a personalized treatment plan for patients with newly diagnosed or relapsed/refractory AML who present with favorable, intermediate, or poor prognostic factors, Develop management protocols for unique adverse events associated with the use of novel therapeutics for AML.

1hr 31mins

20 Jul 2021

Episode artwork

Naval Daver, MD / Harry P. Erba, MD, PhD / Tara Lin, MD / Gail J. Roboz, MD -How I Think, How I Treat in the New Age of AML Care: Personal Perspectives on New Evidence and Innovative Therapeutics

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Go online to PeerView.com/CHU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Led by a panel of expert clinicians, this “How I Think, How I Treat” activity explores the practice-changing evidence that has validated innovative approaches to managing high-risk AML; the use of targeted agents in mutation-defined disease and older populations; and the steady progress being made with antibody-based options for AML. Throughout, the experts highlight their personal reflections on state-of-the-art AML care with a goal of illustrating how their own intra-institutional practices were changed and improved with the use of novel therapeutics. Upon completion of this activity, participants should be better able to: Recognize prognostic patient- and disease-related features, including age, cytogenetics, and mutational status, that are relevant for treatment decisions in AML, Discuss updated efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Manage the unique spectrum of treatment-related adverse events associated with novel therapies used to treat AML.

1hr 39mins

4 Jan 2021

Most Popular

Episode artwork

Naval Daver, MD / Harry P. Erba, MD, PhD / Tara Lin, MD / Gail J. Roboz, MD -How I Think, How I Treat in the New Age of AML Care: Personal Perspectives on New Evidence and Innovative Therapeutics

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/CHU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Led by a panel of expert clinicians, this “How I Think, How I Treat” activity explores the practice-changing evidence that has validated innovative approaches to managing high-risk AML; the use of targeted agents in mutation-defined disease and older populations; and the steady progress being made with antibody-based options for AML. Throughout, the experts highlight their personal reflections on state-of-the-art AML care with a goal of illustrating how their own intra-institutional practices were changed and improved with the use of novel therapeutics. Upon completion of this activity, participants should be better able to: Recognize prognostic patient- and disease-related features, including age, cytogenetics, and mutational status, that are relevant for treatment decisions in AML, Discuss updated efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Manage the unique spectrum of treatment-related adverse events associated with novel therapies used to treat AML.

1hr 39mins

4 Jan 2021

Episode artwork

Naval Daver, MD / Harry P. Erba, MD, PhD / Tara Lin, MD / Gail J. Roboz, MD -How I Think, How I Treat in the New Age of AML Care: Personal Perspectives on New Evidence and Innovative Therapeutics

PeerView Clinical Pharmacology CME/CNE/CPE Video

Go online to PeerView.com/CHU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Led by a panel of expert clinicians, this “How I Think, How I Treat” activity explores the practice-changing evidence that has validated innovative approaches to managing high-risk AML; the use of targeted agents in mutation-defined disease and older populations; and the steady progress being made with antibody-based options for AML. Throughout, the experts highlight their personal reflections on state-of-the-art AML care with a goal of illustrating how their own intra-institutional practices were changed and improved with the use of novel therapeutics. Upon completion of this activity, participants should be better able to: Recognize prognostic patient- and disease-related features, including age, cytogenetics, and mutational status, that are relevant for treatment decisions in AML, Discuss updated efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Manage the unique spectrum of treatment-related adverse events associated with novel therapies used to treat AML.

1hr 39mins

4 Jan 2021

Episode artwork

Acute Myeloid Leukemia - Gail J. Roboz, MD

HMP CME (Video)

MRD in Hematologic Malignancies: Testing Considerations and Challenges

31mins

22 Jan 2020

Episode artwork

Acute Myeloid Leukemia - Gail J. Roboz, MD

HMP CME (Audio)

MRD in Hematologic Malignancies: Testing Considerations and Challenges

31mins

22 Jan 2020

Episode artwork

Measurable Residual Disease (MRD) in AML and ALL - Gail J. Roboz, MD

HMP CME (Audio)

Minimal Residual Disease in Hematologic Malignancies: Testing Considerations and Challenges

22mins

20 Dec 2019

Episode artwork

Measurable Residual Disease (MRD) in AML and ALL - Gail J. Roboz, MD

HMP CME (Video)

Minimal Residual Disease in Hematologic Malignancies: Testing Considerations and Challenges

22mins

20 Dec 2019

Loading